The MIT Corporation — the Institute’s board of trustees — elected nine full-term members, who will each serve for five years; two partial-term members; and three life members, during its quarterly meeting today. Corporation Chair Diane Greene SM ’78 announced the election results; all positions are effective July 1.

The nine full-term members are: Lindsay Androski ’98; Eran Broshy ’79; Ashton Carter; Fiona Chen ’21; Kevin Churchwell ’83; Grace Colón PhD ’95; Diane Hoskins ’79; Pearl Huang ’80; and Ray Rothrock SM ’78. The two partial-term members are: Michael “Mick” Mountz ’87; and Mark Wrighton. The three life members are: Patricia Callahan ’75, SM ’77; Alan Levanthal; and Kenneth Wang ’71.

The Corporation also announced Annalisa L. Weigel ’94, ’95, SM ’00, PhD ’02 as the 2021-2022 president of the Association of Alumni and Alumnae of MIT, effective July 1. She succeeds Charlene C. Kabcenell ’79.

As of July 1, the Corporation will consist of 77 distinguished leaders in education, science, engineering, and industry. Of those, 25 are life members and eight are ex officio. An additional 33 individuals are life members emeritus.

The nine new full-term members are:

Lindsay Androski, founder and CEO, Roivant Social Ventures

Androski earned bachelor’s degrees in biology and history from MIT in 1998. She also attended the University of Chicago Law School and Booth School of Business, where she obtained a JD and an MBA in 2005. Androski is the founder, president, and CEO of Roivant Social Ventures, the impact investing arm of Roivant Sciences, which invests in and incubates new companies with potential to improve health care access and outcomes for underserved groups and geographies. Androski has also worked as a trial lawyer, including as assistant U.S. attorney in Alexandria, Virginia, where she led investigations and prosecutions of high-profile cybercrime and national security cases and received the highest awards given by several federal agencies. Androski left the practice of law in 2016 after an MIT classmate urged her to join and help Roivant Sciences, where she has led a team responsible for in-licensing or acquiring more than 30 pharmaceutical drug candidates, resulting in the launch of 16 biotechnology subsidiaries.

Eran Broshy, former chairperson and CEO, inVentiv Health

Broshy earned his bachelor’s in civil engineering from MIT in December 1978 and went on to complete his master’s in civil engineering at Stanford University and his MBA at Harvard University in 1984. He has spent more than 35 years as a health care executive, building high-growth public and private health care businesses as CEO, board chair, director, strategist, and investor. Broshy served for over a decade as CEO and chairman of inVentiv Health, taking the company public and turning it into the leading global provider of outsourced clinical and commercial services to pharmaceutical and life sciences companies, growing it to a $1 billion leader in the industry before taking it private a decade later. Over the last 10 years, Broshy has served as a board director on multiple private and public boards, and has partnered with private equity firms to support their health care investment efforts.

Ashton Carter, director, Belfer Center for Science and International Affairs, Harvard Kennedy School

Ashton “Ash” Carter earned his bachelor’s degrees in physics and medieval history at Yale University, and he received his doctorate in theoretical physics from Oxford University, where he was a Rhodes Scholar. Carter serves as the director of the Belfer Center for Science and International Affairs at Harvard University’s Kennedy School and is an Innovation Fellow at MIT. Most recently, Carter served as the 25th U.S. secretary of defense. For over 35 years inside government under presidents of both political parties as well as in the private sector, Carter has leveraged his extraordinary experience in national security, technology, and innovation to defend the United States and make a better world.

Fiona Chen, MIT senior in economics

Chen is an MIT senior slated to graduate June 4 with a bachelor’s degree in economics and mathematics. She is actively involved in research in the economics department, and has worked on a range of timely projects including the feasibility of a universal health care system in the U.S., the effects of technological innovation on the labor market, and the relationship between sleep deprivation and poverty. Her thesis covers the effects of social isolation on students’ well-being and academic performance. This fall, she will begin a PhD in economics at Harvard University as a Paul and Daisy Soros Fellow.

Kevin Churchwell, president and CEO, Boston Children’s Hospital

Churchwell earned his bachelor’s degree from MIT in biology in 1983 and his MD from Vanderbilt Medical School. Churchwell is currently the Robert and Dana Smith Associate Professor of Anesthesia at Harvard Medical School. Since joining Boston Children’s as its executive vice president of health affairs and COO in 2013, he has brought the same passion for enhancing patient safety, employee safety, and the family experience that defined his tenure as CEO of both the Nemours/Alfred I. duPont Hospital for Children in Delaware and Monroe Carell Jr. Children’s Hospital in Tennessee. As an advocate for equity, diversity, and inclusivity, Churchwell is also responsible for establishing three of the 11 Offices of Health Equity and Inclusion at hospitals across the U.S. and Canada, including the office at Boston Children’s, which he founded in 2016.

Grace Colón, president and CEO, InCarda Therapeutics, Inc.

Colón received her bachelor’s degree in chemical engineering from the University of Pennsylvania in 1988 and her PhD in chemical engineering from MIT in 1995. Colón has over 25 years of experience in biopharma, genomics, health care, and industrial biotechnology. She is currently CEO and president of InCarda Therapeutics, a clinical stage therapeutics company developing therapies for areas of high unmet medical need in cardiology, initially focused on atrial fibrillation. Formerly, she was a partner and senior advisor at New Science Ventures, a venture capital firm with over $700 million under management. Before that, she co-founded Pyranose Biotherapeutics, a biologics discovery platform company, and was the founding president of the Industrial Products Division of Intrexon Corporation, where she established a new division and labs focused on leveraging synthetic biology for bioindustrial applications such as biofuels and renewable chemicals.

Diane Hoskins, co-CEO and chairperson, Gensler

Hoskins earned her bachelor’s in architecture from MIT in 1979 and her MBA from the Anderson School at the University of California at Los Angeles in 1987. She is a co-CEO at Gensler, the world’s largest architecture design firm. Hoskins has broad responsibility running the firm’s day-to-day operations, which span more than 5,500 employees networked across 50 offices in the America, Europe, Asia, and the Middle East. She is chair of Gensler’s board of directors. Hoskins serves on several MIT alumni bodies and was the featured speaker at a 2018 MIT event celebrating the 150th anniversary of the Institute’s inaugurating the country’s first architecture program.

Pearl Huang, president and CEO, Cygnal Therapeutics

Huang earned a bachelor’s degree in biology from MIT in 1980 and a PhD in molecular biology from Princeton University in 1990. Huang began her career at Merck Research Labs in 1990 before moving to DuPont Pharmaceuticals as the director of cancer biology. Huang then joined GlaxoSmithKline before returning to Merck to serve as vice president and oncology franchise integrator, a strategic role heading up translational medicine and managing the then-nascent oncology pipeline. In 2010, Huang co-founded Beigene in China, where she served as chief scientific officer until 2012. She then held leadership roles at GlaxoSmithKline and Roche before joining Cygnal Therapeutics, the role she currently holds. She is also a venture partner at Flagship Pioneering, the venture creation firm that founded Cygnal Therapeutics.

Ray Rothrock, philanthropist, venture capitalist, advocate for clean energy

Rothrock earned a bachelor’s degree in nuclear engineering from Texas A&M University, a master’s degree in nuclear engineering from MIT, and an MBA with distinction from Harvard Business School. Rothrock is the executive chairperson of RedSeal, a cyber security company. Prior to RedSeal he was a general partner at Venrock, where he invested in 53 companies, including over a dozen in cybersecurity. As a private venture investor, he has backed companies such as ROKU and Nest. He is on the board of Check Point Software and ROKU. Rothrock is a speaker on cybersecurity, energy, and technology, and was the 2012-2013 chair of the National Venture Capital Association.

The two new partial term members are:

Mick Mountz, technology advisor, Kacchip, LLC

Michael “Mick” Mountz earned a bachelor’s degree in mechanical engineering from MIT in 1987 and an MBA from Harvard University in 1996. Mountz is the former CEO and founder of Kiva Systems, now Amazon Robotics. Mountz founded Kiva in 2003 after spending time in high tech product development, manufacturing, and marketing at Motorola, Apple, and Webvan. Kiva Systems’ order fulfillment solution deploys hundreds of thousands of mobile robots into ecommerce pick-pack-and-ship fulfillment centers and kicked off the wave of robotics automation now sweeping the material handling world. In 2009 Kiva was ranked No. 6 on the Inc. 500 list of the fastest growing private companies in America, and in 2012 Fast Company recognized Kiva as the 23rd most innovative company in the world. That same year, Amazon acquired Kiva. Mountz holds over 40 U.S. technology patents and is a member of the National Inventors Hall of Fame. He is now an active hardware advisor and investor in Boston.

Mark Wrighton, chancellor emeritus and professor of chemistry, Washington University in St. Louis

Wrighton earned his bachelor’s degree in chemistry from Florida State University in 1969 and his PhD in chemistry from the Caltech in 1972. Wrighton started his career at MIT in 1972 as associate professor of chemistry. He was appointed associate professor in 1976 and professor in 1977. In 1989 he was appointed the first holder of the Ciba-Geigy Professorship in Chemistry. He was head of the Department of Chemistry from 1987 to 1990 and became MIT’s provost in 1990, a post he held until the summer of 1995. From 1995 until 2019 he served as the chancellor and CEO at Washington University in St. Louis. He is now a professor and chancellor emeritus at the school.

The three new life members are:

Patricia Callahan, former senior executive vice president and CAO, Wells Fargo and Company

Callahan earned her bachelor’s degree in 1975 and her master’s degree in 1977, both from MIT. That year she began working at Wells Fargo, serving in various roles in operations, finance, and product management. She served as head of systems, operations, and finance for the commercial real estate group from 1991 to 1993 and of wholesale banking from 1997 to 1998; head of corporate human resources from 1993 to 1996 and again from 1998 to 2005, and head of compliance and enterprise risk management from 2005 to 2008. From 2008 to 2011, Callahan successfully led a large banking merger, and in 2011 was promoted to chief administrative officer, responsible for managing 2,300 team members in corporate communications, corporate social responsibility, enterprise marketing, government relations, and human resources. She retired in 2015.

Alan Leventhal, chairperson, CEO, and founder, Beacon Capital Partners

Leventhal earned his bachelor’s degree from Northwestern University in 1974 and his MBA from the Amos Tuck School at Dartmouth College in 1976. He serves as chair and CEO of Beacon Capital Partners, one of the leading owners and managers of office and life science properties of the United States. He has held board memberships with Boston University, the Damon Runyon Cancer Research Foundation, the Leventhal Map and Education Center, the Friends of Post Office Square, Northwestern University, and the Amos Tuck School. He was awarded the New England Entrepreneur of the Year in 2004 by Ernst and Young and the Outstanding CEO Award in 1996 and 1997 by Realty Stock Review.

Kenneth Wang, president, U.S. Summit Company

Wang received his bachelor’s degree in economics in 1971 and his MBA from Harvard Business School in 1976. After graduating from Harvard, he was employed by Bank of America’s New York Corporate Office’s transportation group, specializing in ship finance. In 1980, he joined a family-owned private company, Oceanic Petroleum Corporation (OPC), which built and operated an oil refiner and gas station chain in Thailand and a joint venture refinery in Singapore. OPC’s operations also included an oil terminal in Hong Kong and LPG terminals in Singapore and Malaysia. During the sale of most of these petroleum-related assets in the 1980s and 1990s, Wang became involved in U.S. Summit Company, another family company primarily engaged in marketing and distribution of ethical pharmaceuticals, OTC products, medical products, and industrial chemicals through operating subsidiaries in multiple Asian markets.

President of the Association of Alumni and Alumnae of MIT:

Annalisa Weigel, senior director, Fairmont Consulting Group

Weigel earned a bachelor’s degree in aeronautics and astronautics in 1994, a bachelor’s in science, technology, and society in 1995, a master’s in aeronautics and astronautics in 2000, and a PhD in technology, management, and policy in 2002, all from MIT. She also earned a master’s in international affairs in 1998 from George Washington University. Weigel is a senior director of the Fairmont Consulting Group, having joined the firm in 2012. She provides counsel to CEOs, leadership teams, boards, and investors on growth strategy and transactions in the aerospace, defense, and government services sectors. Previously, she was on the faculty at MIT with a dual appointment in aeronautics and astronautics and engineering systems, where she spent eight years researching and teaching in systems design, continuous process improvement, and engineering innovation.